In line with these results, protein analysis revealed that combination treatment in Eμ-myc/bcl-2 and U2932-4RH lymphomas displayed aberrations in Myc and Bcl-2 expression as well as increased caspase activation (Figure 4c). This evidence concerns the gene BCL2 and lymphoma.